The race to the finish line—the time between an empty nest and retirement—is tightening. A major generational shift has taken place, and it’s having a huge impact on when and how we save and plan.
Most older baby boomers like myself had children in their 20s and empty nests by age 50. They used that time to accumulate enough money to retire. When my children were in high school, their friends’ parents were in their late 30s or early 40s. It was unusual to run across 50-somethings at a PTA meeting or high school basketball game.
I don’t need a bunch of expensive research to confirm what I see with my own eyes: Couples are marrying later in life, having children later, and even spacing them out more. My own unscientific survey confirmed this. My oldest son just turned 50, and his two children are 14 and 12. My stepdaughter is 36, and she has a nine-year-old and four-year-old. They’re right in line with their peer group.
So, assuming our grandchildren go to college, my children could easily be in their early 60s before their kids are off their payroll. Even if they push retirement back to 68, the time allotted for their race to the finish line has been cut by about 50%. If they had followed in their parents’ footsteps and waited until the nest was empty to get serious about retirement, they’d damn sure have to be world-class sprinters.
Top 5 High Tech Stocks To Invest In 2015: Protalix Biotherapeutics Inc (PLX)
Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. Its ProCellEx protein expression system is built on flexible custom-designed bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures. In June 2010, it had completed the preliminary phase I clinical trial of PRX- 105.
Taliglucerase alfa is a plant cell expressed recombinant glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease. The Company has commenced pre-clinical studies of an oral form of taliglucerase alfa. Its oral taliglucerase alfa is a plant cell expressed form of GCD that is naturally encapsulated within carrot cells genetically engineered to express the GCD enzyme. Pre-clinical studies of oral taliglucerase alfa demonstrate the stability of the enzyme in the cell and the capacity of the cell’s cellulose wall to protect the enzyme against degradation in the digestive tract in an in-vitro model of the stomach and intestines. Additionally, rats fed with lyophilized carrot cells expressing GCD have accumulated the active enzyme in the target organs; the spleen and liver. As of December 31, 2010, the Company had completed Phase III Clinical Trial.
The Company is developing PRX-102, i ts plant cell expressed modified version of the recombinant ! alpha-GAL-A protein, a therapeutic enzyme for the treatment of Fabry disease. Fabry disease is a rare, hereditary, genetic lysosomal storage disorder in humans caused by an X-lined deficiency of the alpha-GAL-A enzyme. The Company is in the animal evaluation testing phase of the development of PRX-102, which tests are based on a mouse model for Fabry disease.
Protalix Ltd. is a wholly owned subsidiary of the Company is licensed the rights to certain technology under a research and license agreement with Yissum Research and Development Company (Yissum) and the Boyce Thompson Institute, Inc. Pursuant to the agreement, the Company is developing PRX-105, a plant cell-based acetylcholinesterase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications, as well as in a biodefense program and an organophosphate-based pesticide treatment program.
As of December 31, 2010, its in-vitr o experiments of PRX-105 have shown that the acetylcholinesterase enzyme in its ProCellEx protein expression system demonstrates biological activity on biochemical and cellular levels. In addition, early animal studies demonstrated that the acetylcholinesterase expressed in its ProCellEx protein expression system was able to treat animals exposed to the nerve gas agent analogues, both when injected with its acetylcholinesterase product candidate immediately before exposure or when injected after exposure. In March 2010, it initiated a preliminary phase I clinical trial of PRX-105, which the Company completed in June 2010.
pr-antiTNF is a candidate for the treatment of certain autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing, spondylitis, psoriatic arthritis and plaque psoriasis. The Company has designed the antiTNF as pr-antiTNF. pr-antiTNF is a plant cell-expressed recombinant fusion protein ma de from the soluble form of the human TNF receptor (TNFR), f! used to t! he Fc component of a human antibody domain. pr-antiTNF has an identical amino acid sequence to Enbrel and its in-vitro and preclinical animal studies have demonstrated that pr-antiTNF exhibits similar activity to Enbrel. Specifically, pr-antiTNF binds TNF thereby inhibiting it from binding to cellular surface TNF receptors and protects L929 cells from TNF-induced apoptosis in a dose-dependent manner.
The Company competes with Genzyme, Actelion, Crucell N.V., Biolex, Inc., Chlorogen, Inc., Greenovation Biotech GmbH, Symbiosys, Novartis AG/Sandoz Pharmaceuticals, BioGeneriX AG, Stada Arzneimittel AG, BioPartners GmbH and Teva.
- [By Maxx Chatsko]
Industrial biotech isn’t the only industry headed to Brazil. Protalix (NYSEMKT: PLX ) entered into a technology transfer agreement with Brazil’s Ministry of Health last week that will pay the company $280 million. The deal is big news for Protalix’s first product, Elelyso/Uplyso, which was developed with partner Pfizer (NYSE: PFE ) . The treatment is approved as an enzyme replacement therapy, or ERT, for adults with type 1 Gaucher disease, and it marks a huge step forward for the future of biomanufacturing. In the following video, Fool contributor Maxx Chatsko explains what this means for the product’s commercialization and the adoption of Protalix’s novel plant cell-based expression system for therapeutic proteins.
- [By Keith Speights]
Other investors might wish that Pfizer would use some of its cash to acquire a few smaller companies. Protalix BioTherapeutics (NYSEMKT: PLX ) has been mentioned as one possible candidate. The two companies already partner together on Gaucher disease drug Elelyso. In February, Protalix spurred rumors that Pfizer could be interested in buying the company after it announced that it had engaged Citigroup to pursue a “broad array of strategic alternatives.”
Top 5 High Tech Stocks To Invest In 2015: Vapor Corp (VPCO)
Vapor Corp (Vapor), incorporated in 1987, is engaged in designing, marketing and distributing electronic cigarettes and accessories under the Fifty-One, Krave, VaporX, EZ Smoker, Green Puffer, Americig, Fumre Hookah Stix and Smoke Star brands. Electronic cigarettes or e-cigarettes, are battery-powered products that enable users to inhale nicotine vapor without smoke, tar, ash, or carbon monoxide. Electronic cigarettes look like traditional cigarettes and consists of three functional components: a mouthpiece, which is a small plastic cartridge that contains a liquid nicotine solution; a heating element that vaporizes the liquid nicotine so that it can be inhaled; and the electronics, which include: a lithium-ion battery, an airflow sensor, a microchip controller and an light emitting diode (LED), which illuminates to indicate use. When a user draws air through the electronic cigarette, the air flow is detected by a sensor, which activates a heating element that vaporizes th e solution stored in the mouthpiece/cartridge, the solution is then vaporized and it is this vapor that is inhaled by the user. The cartridge contains either a nicotine solution or a nicotine free solution, either of which may be flavored. The Company offers rechargeable and disposable electronic cigarettes in two varieties: a two-piece unit, which the Company markets under its DUO product line; and a three-piece unit, which the Company markets under its TRIO product line.
The DUO’s 2-part construction (battery component and cartridge) features a disposable all-in-one atomized cartridge (also known as a cartomizer). This cartomizer is replaced when the nicotine or nicotine free solution is depleted from use. The all-in-one configuration eliminates the need for maintenance of a separate atomizer and maintains consistent performance of the e-cigarette over time.
The TRIO’s 3-part construction (battery compone nt, atomizer, and filter cartridge) features a separate atom! izer from the cartridge; the atomizer is reused and requires separate maintenance over its useful life. Replacement atomizers are available for sale and are easily serviceable by the user. In the TRIO, the only component that needs to be routinely replaced is the refill cartridge (either with or without nicotine).
The Company’s electronic cigarettes are sold in kits. In addition to kits the Company sells replacement batteries, replacement mouthpieces that contain the liquid solution and atomizer, for its two-piece configurations as well as mouthpieces with the liquid solution and separate atomizers for its three-piece units. In addition to the Company’s electronic cigarette products the Company sells an assortment of accessories, including chargers and simple and fashionable cases. The Company also offers refill cartridges and accessories for its electronic cigarettes. The Company’s refill cartridges consist of assorted flavors and nicotine levels (including car tridges without nicotine).
The Company competes with Altria Group, Inc. and Reynolds American Inc.,
- [By James E. Brumley]
Fans and investors of American Heritage International Inc. (OTCBB:AHII) – not to mention frenemies Vapor Corp. (OTCMKTS:VPCO) and Victory Electronic Cigarettes Corp. (OTCMKTS:ECIG) – can all breathe a sigh of relief today. As it turns out, while the electronic cigarette industry is more than likely be regulated by the FDA, it’s going to be regulated in such a way that tends to favor the likes of AHII, ECIG, and VPCO.
- [By John Udovich]
Last week, I talked about small cap electronic cigarette stocks Vapor Corp (OTCMKTS: VPCO) and Hop-On Inc (OTCMKTS: HPNN) as being among the last of the e-Cig stocks not controlled by “Big Tobacco,” but Victory Electronic Cigarettes Corp (OTCMKTS: ECIG), mCig Inc (OTCBB: MCIG) and American Heritage International (OTCBB: AHII) are also positioning themselves or their technology to exploit opportunities in the e-Cig market or even in marijuana or cannabis. Last year, industry experts were already saying that US retail sales of e-cigarettes could reach $1 billion for the year for roughly 1% of the country’s cigarette market. That number might appear small, but its more than double 2012 sales as sales increasingly move off the Internet and into more mainstream retailers thanks to their positioning as a “healthier” alternative to smoking.
Top 5 High Tech Stocks To Invest In 2015: Essex Rental Corp (ESSX)
Essex Rental Corp., incorporated on August 21, 2006, through its subsidiaries, is engaged in providing of lifting equipment (including lattice-boom crawler cranes, truck cranes and rough terrain cranes, tower cranes, and other lifting equipment) used in an array of construction projects. In addition, it provides product support including installation, maintenance, repair, and parts and services for its equipment provided to customers and customer owned equipment. It operates in three segments: equipment rentals, equipment distribution, and parts and service. Its subsidiaries wholly owned subsidiaries include Essex Holdings, LLC (Holdings), Essex Crane Rental Corp. (Essex Crane), Essex Finance Corp. (Essex Finance), CC Acquisition Holding Corp. (CC Acquisition), Coast Crane Company, (Coast Crane) and Coast Crane Ltd. (Coast Crane Ltd.).
The Company supply a variety of lifting solutions for construction projects related to power generation, petro-chemical, refin eries, water treatment and purification, bridges, highways, hospitals, shipbuilding, offshore oil fabrication and industrial plants, and commercial and residential construction. It rent its equipment bare, meaning without supplying an operator and, in exchange for a fee, make arrangements for the transportation and delivery of equipment.
Essex Crane is a provider of lattice-boom crawler crane and attachment rental services and possesses fleets of such equipment in the United States. As of December 31, 2011, Essex Crane’s fleet size stands at more than 350 lattice-boom crawler cranes and various types of attachments, which are made available to clients depending on their lifting requirements, such as weight, pick and carry aspects, reach and angle of reach.
Coast Crane is a provider for lifting solutions throughout Western North America, Alaska, Hawaii, Guam and the South Pacific. Through Coast Crane, it provides both used and new towers cranes, bo om trucks, rough terrain cranes and other lifting equipment ! to customers in the infrastructure, energy, crane rigger/operator, and municipal, commercial and industrial construction sectors. Coast Crane’s operations are headquartered in Seattle, Washington and its products are rented and sold through a regional network including 11 branch locations. In addition to providing crane rental services, Coast Crane is a crane distributor of self-erecting tower cranes, rough terrain cranes, boom trucks and all terrain cranes in its West Coast territories.
The Company offer for rent crawler cranes and attachments, rough terrain cranes, boom trucks, tower cranes, and other construction related rental equipment. It also offer transportation, rigging and repair and maintenance services while equipment is on rent. It rent its fleet of over 1,000 cranes and attachments and other lifting equipment to a variety of engineering and construction customers under contracts, most of which have rental periods of between 4 and 18 months. The contracts typically provide for an agreed rental rate and a specified rental period. Transportation services revenue is derived from the management of the logistics process by which its rental equipment is transported to and from customers’ construction sites, including the contracting of third party trucking for such transportation.
The Company offers a variety of construction equipment products for sale, including tower cranes, boom trucks, rough terrain cranes and other lifting equipment used in the construction industry. The revenue from retail equipment sales is primarily driven by the level of construction activity in a particular geographic region.
Parts and Service
The Company is a parts distributor for various lifting equipment manufacturers and routinely sells parts to its customers in the construction industry. It also provides repairs and maintenance services for customers that own their own equipment and request its ! services ! at one of its service center locations. Its customers for these ancillary services are its rental customers, customers that own their own equipment and those who purchase new and used equipment from it.
The Company competes with ALL Erection & Crane Rental, Bigge Crane and Rigging, Co., Lampson International, Maxim Crane Works, M.D., Morrow Equipment Rental, Western Pacific Crane and Equipment and AmQuip Crane Corp.
- [By Monica Gerson]
Essex Rental (NASDAQ: ESSX) is projected to post a Q4 loss at $0.10 per share on revenue of $22.55 million.
Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets
Top 5 High Tech Stocks To Invest In 2015: Oncothyreon Inc .(ONTY)
Oncothyreon Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its primary product candidate, Stimuvax is in two phase III clinical trials for the treatment of non-small cell lung cancer. The company is also developing PX-866, a small molecule that is in phase II trials for various cancer indications. In addition, it engages in the preclinical development of ONT-10, a cancer vaccine; and ONT-701, a pan-inhibitor of the B-cell lymphoma-2 family of anti-apoptotic proteins. The company operates primarily in the United States and Canada. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.
- [By James E. Brumley]
On paper, Oncothyreon Inc. (NASDAQ:ONTY) doesn’t look like a particularly compelling investment. The pre-revenue biotech company is poised to keep booking sizable losses as it continues to work on its lung cancer drug tecemotide (formerly Stimuvax), which has rejected by the FDA last year but is still being reworked for a slightly different illness than was being targeted initially. And, with no other Phase 3 drug in its pipeline, traders may be rightfully wondering if there’s any real catalyst for ONTY in the foreseeable future.
- [By Lauren Pollock]
Among the companies with shares expected to actively trade in Wednesday’s session are Mako Surgical Corp.(MAKO), Ascena Retail Group Inc.(ASNA) and Oncothyreon Inc.(ONTY)
- [By EP Vantage]
Although the subgroup on which this decision is based was large, many will still consider this a risky basis for further study. Some investors thought it was a risk worth taking: shares in Oncothyreon (ONTY), which licensed the drug to Merck and saw its valuation more than halve on news of the Start failure, were trading 22% higher this morning at $2.19; Merck KGaA stock was little changed. But, in the meantime, tecemotide will struggle to shake off the stain of past failure.
- [By António Costa]
Oncothyreon Inc (NASDAQ: ONTY) is firming just above key support at $1.78 and a triangle has taken shape over the last few weeks. The stock is starting to show signs of accumulation with high upside days and low downside days. This stock is poised for a move and I suspect that it will explode to the upside. In addition, Inside trading has been very active over the last month. They are buying now after pausing years.
Top 5 High Tech Stocks To Invest In 2015: Financial Engines Inc.(FNGN)
Financial Engines, Inc. and its subsidiaries provide independent, technology-enabled portfolio management services, investment advice, and retirement income services to participants in employer-sponsored defined contribution plans. The company helps investors plan for retirement by offering personalized plans for saving and investing, as well as by providing assessments of retirement income needs and readiness. Its services include Professional Management, a discretionary managed account service designed for plan participants who want personalized and professional portfolio management services, investment advice, and retirement income services from an independent investment advisor; Online Advice, an Internet-based non-discretionary service that offers personalized advice to plan participants who manage their portfolios directly; and Retirement Evaluation, a retirement readiness assessment provided to plan participants upon plan rollout. The company delivers its services t o plan sponsors and plan participants primarily through connections to eight retirement plan providers in the United States. Financial Engines, Inc. was founded in 1996 and is headquartered in Palo Alto, California.
- [By GURUFOCUS]
Our biggest contributor this quarter was Financial Engines, Inc. (FNGN), which provides personalized independent investment management and advice to employees for their retirement plans. The stock rose 26.0%. Revenues grew an impressive 29% in the first quarter, driven by additional corporate clients, more employee participation and stock market appreciation. The company recently introduced “Income Plus” an alternative to “target date” fund offerings, which is being well received and opens up potential new growth opportunities.